The 2008 carton was not in the 2003 box
Claim: daily Cialis launched with the brand. Label: false. Strike: November 2003 cleared as-needed 5, 10 and 20 mg. File the daily 2.5 or 5 mg strengths as a later price.
Men who now swallow a pale daily chip often assume that tablet sat on the first US shelf. It did not. Lilly ICOS won erectile-dysfunction clearance on 21 November 2003 for a tablet taken before sex. The starting as-needed dose was 10 mg, with 5 mg and 20 mg as the adjusters. TIME put Cialis on a 2003 inventions list for the long window, not for a breakfast habit.
Five years later the company asked for a different habit. On 8 January 2008 the FDA cleared tadalafil 2.5 mg and 5 mg once daily. Same molecule. New carton. New intent: keep a low level in plasma so the clock no longer owns the evening. The pharmacology that made that ask possible lives in the tadalafil reference. This file is about who built the molecule, who paid to finish it, and why the cheap-looking daily strengths were a second commercial bet.
If you only remember one date pair, remember this. 2003 sold duration. 2008 sold presence. Confusing the two is how people invent a launch story that never happened.
Bothell wrote the code. Indianapolis did not.
Claim: every PDE5 blockbuster came out of a giant's lab. Label: wrong address. Strike: tadalafil began as IC351 at ICOS Corporation in Bothell, Washington, a few miles north of Seattle. File: a mid-size biotech that lived on inflammation and cell-signalling bets, not a lifestyle-medicine factory.
ICOS opened in 1989. For most of the 1990s it burned cash across several programs and looked like the kind of company that needed one validating asset. Phosphodiesterase chemistry was one of those bets. In 1993 the Bothell group started cardiovascular work on IC351. A patent followed in 1994. Phase 1 dosing in people started in 1995. Phase 2 in men with erectile dysfunction opened in 1997. None of that is a Lilly origin story.
The structure was not a sildenafil twin. That mattered later for clearance and for the muscle ache some men still blame on the brand. What mattered first was simpler: a small Washington shop held a PDE5 inhibitor just as Pfizer proved the target was real money. ICOS suddenly had something a partner would pay to finish.
Glaxo walked. Lilly signed.
Claim: Lilly discovered Cialis. Label: partner, not inventor. Strike the origin myth, then file the 1998 joint venture.
ICOS did not start with Lilly. In August 1991 it had a discovery pact with Glaxo Wellcome. Profits on anything that came out of that work were meant to split 50/50. Glaxo let the pact lapse in 1996. The compounds were not in Glaxo's core markets. IC351 stayed in Bothell.
Eli Lilly arrived in 1998 and formed Lilly ICOS LLC. That is the deal that turned a code into a global trial machine. Lilly brought phase 3 infrastructure, regulators, and a sales force that could walk into primary-care offices. ICOS brought the molecule and the people who understood why it lingered. Two years later the joint venture filed the new-drug application under the generic name tadalafil and the trade name Cialis.
A mid-size biotech almost never finishes a lifestyle drug alone. The Glaxo exit is the part most origin blurbs skip. Without that lapse, the later daily 2.5 or 5 mg carton might have worn a different badge.
A 17.5-hour half-life is what priced a daily chip
| Year | What ICOS or Lilly actually held | What the claim usually says |
|---|---|---|
| 1993-1995 | IC351 in Bothell; patent; phase 1 | Lilly invented a sex pill |
| 1996 | Glaxo pact lapses | Big Pharma always wanted it |
| 1998-2000 | Lilly ICOS; NDA as Cialis | ICOS sold a finished brand |
| 2003 | PRN 5/10/20 mg, 36-hour window | Daily 2.5 or 5 mg launched |
| 2008 | Once-daily 2.5 and 5 mg cleared | Same carton, new sticker |
Claim: marketers invented the weekend pill, then invented daily Cialis to sell more bottles. Label: backwards. Strike: the nickname and the later daily strengths both sit on one measured number. File: tadalafil's terminal half-life is about 17.5 hours.
Sildenafil is gone in a workday. Tadalafil is not. After a single as-needed tablet, useful concentrations stretch toward 36 hours. Porst put that window on a slide at the 2002 AUA meeting in Orlando. Brock's five-trial stack, published the same year, gave the efficacy numbers that carried Europe in late 2002 and the US in 2003. The weekend line was a pharmacokinetic fact with a slogan attached, not a slogan in search of a fact.
Once you have a half-life that long, a low daily swallow stops looking exotic. Forgue's 2006 work showed that after about five once-daily doses, a 2.5 mg tablet produces exposure in the neighbourhood of a 4 mg intermittent dose, and 5 mg daily sits near 8 mg. Steady state, not a bigger bang. That arithmetic is why Lilly could price a breakfast tablet without inventing a new compound. The trial read of those strengths is in the Cialis daily reviews, not here.
The weekend window paid for the brand before breakfast did
By 2003 the category was no longer empty. Sildenafil had owned the name since 1998. Vardenafil arrived in the same season as Cialis. A second-to-market tablet does not win by shouting louder about peak firmness. It wins by changing the clock. Lilly ICOS sold that clock hard: take it Friday, still be in range Saturday night.
Claim: tadalafil beat Viagra on the erection itself. Label: oversold. Strike: response rates in the early program sat in the same league as the rest of the class. File: duration was the commercial wedge. Food did not blunt the tablet the way a greasy plate blunts sildenafil. Those two facts - long window, no meal penalty - are what let a Bothell molecule take share from a household name.
The nitrate rule was inked on day one and never moved. Nitrates and tadalafil share the nitric-oxide and cyclic-GMP path. Stack them and blood pressure can fall to a dangerous level. Because the half-life is long, the hold lasts more than a workday. That line belongs in every origin file, because the same linger that priced the weekend also priced the risk.
January 2008: 2.5 or 5 mg daily get a price of their own
Claim: daily Cialis is just a weaker PRN tablet taken every morning for no reason. Label: category error. Strike the 'weaker' frame. File the 2008 indication as a schedule, not a potency contest.
Lilly's 8 January 2008 release was blunt. Men on 2.5 mg or 5 mg once daily, without tying the swallow to sex, improved erectile function versus placebo in three phase 3 studies. The as-needed 5, 10 and 20 mg tablets stayed on the market. Patients could now pick a regimen with a clinician instead of pretending one carton served both lives.
That is a pricing and habit decision as much as a chemistry one. A daily 2.5 or 5 mg bottle is a month of swallows. An as-needed bottle is a handful of evenings. Brand Cialis made the daily habit look expensive. Generic tadalafil later flattened that argument, which is why the schedule split now turns on frequency and planning, not on a luxury premium.
The 5 mg daily strength later picked up a second job. In 2011 the same tablet was cleared for lower-urinary-tract symptoms of benign prostatic hyperplasia, and for men who had both problems. On-demand 20 mg cannot treat a night-time stream. Only a tablet that is present every day can. The Bothell half-life, again, is what made that second label possible.
What this origin file refuses to reprint
ICOS Corporation opens in Bothell, Washington, around inflammation and signalling, not a lifestyle brand.
Glaxo Wellcome discovery pact; Glaxo lets it lapse. IC351 stays in Bothell.
IC351 cardiovascular work, 1994 patent, 1995 phase 1, 1997 phase 2 in ED.
Lilly ICOS joint venture; NDA filed as tadalafil / Cialis.
AUA 36-hour data; Europe late 2002; US FDA 21 November 2003 for PRN 5/10/20 mg.
Lilly buys ICOS. FDA clears once-daily 2.5 and 5 mg on 8 January 2008.
Adcirca 40 mg for PAH; then daily 5 mg for BPH and for ED plus BPH together.
A development story that turns into a mini-label is a clone of the tadalafil reference. This page will not walk the full CYP3A4 list, the CrCl cuts, or the counselling script. Those belong on the medicine page. Here the job is narrower: who held the code, who paid, which carton came first, and why 2.5 or 5 mg daily is a 2008 price.
Two later brands confuse the file if you let them. Adcirca is tadalafil 40 mg once daily for pulmonary arterial hypertension, cleared after the PHIRST walk-distance trial - a different disease, a different dose, a different carton. It is not a 'strong Cialis.' And the 2007 Lilly buyout of ICOS, at about $2.3 billion, closed the Bothell company's independent life. The molecule outlived the shop that drew it. That ending is common in biotech. It is still worth stating, because people keep assigning the discovery to Indianapolis.
If you want endpoints, open the trial-number review. If you want to pick a calendar, open the daily versus PRN split. This page files the bench.
File: Bothell priced the linger, then priced the weekday
Claim left standing after the strikes: a small Bothell bench wrote a long-half-life PDE5 inhibitor, a lapsed Glaxo pact left it free, Lilly finished the trials, and the first US money was made on a 36-hour as-needed tablet. The daily 2.5 or 5 mg strengths were a second, deliberate carton - January 2008 - once steady-state arithmetic showed a breakfast swallow could hold the same enzyme without a new molecule.
That is the development file. It is not a verdict on whether you should take the daily chip or the PRN one. It is the reason both options exist on one INN. Bring a nitrate list to whoever actually prescribes. The linger that sold the weekend still sells the risk.